Literature DB >> 28470176

Dyslipidaemia: The PCSK9 adventure - humanizing extreme LDL lowering.

Michael D Shapiro1, Sergio Fazio1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28470176     DOI: 10.1038/nrcardio.2017.66

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

1.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

2.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

Review 3.  Targeting PCSK9 for therapeutic gains.

Authors:  Michael D Shapiro; Sergio Fazio; Hagai Tavori
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

4.  Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.

Authors:  Paul M Ridker; Jean-Claude Tardif; Pierre Amarenco; William Duggan; Robert J Glynn; J Wouter Jukema; John J P Kastelein; Albert M Kim; Wolfgang Koenig; Steven Nissen; James Revkin; Lynda M Rose; Raul D Santos; Pamela F Schwartz; Charles L Shear; Carla Yunis
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

5.  Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.

Authors:  Kausik K Ray; Ulf Landmesser; Lawrence A Leiter; David Kallend; Robert Dufour; Mahir Karakas; Tim Hall; Roland P T Troquay; Traci Turner; Frank L J Visseren; Peter Wijngaard; R Scott Wright; John J P Kastelein
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

6.  Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.

Authors:  Paul M Ridker; James Revkin; Pierre Amarenco; Robert Brunell; Madelyn Curto; Fernando Civeira; Marcus Flather; Robert J Glynn; Jean Gregoire; J Wouter Jukema; Yuri Karpov; John J P Kastelein; Wolfgang Koenig; Alberto Lorenzatti; Pravin Manga; Urszula Masiukiewicz; Michael Miller; Arend Mosterd; Jan Murin; Jose C Nicolau; Steven Nissen; Piotr Ponikowski; Raul D Santos; Pamela F Schwartz; Handrean Soran; Harvey White; R Scott Wright; Michal Vrablik; Carla Yunis; Charles L Shear; Jean-Claude Tardif
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

7.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Authors:  Marc S Sabatine; Robert P Giugliano; Stephen D Wiviott; Frederick J Raal; Dirk J Blom; Jennifer Robinson; Christie M Ballantyne; Ransi Somaratne; Jason Legg; Scott M Wasserman; Robert Scott; Michael J Koren; Evan A Stein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

8.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Authors:  Jennifer G Robinson; Michel Farnier; Michel Krempf; Jean Bergeron; Gérald Luc; Maurizio Averna; Erik S Stroes; Gisle Langslet; Frederick J Raal; Mahfouz El Shahawy; Michael J Koren; Norman E Lepor; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; John J P Kastelein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

9.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors:  Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

Review 10.  Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.

Authors:  Marianne Abifadel; Sandy Elbitar; Petra El Khoury; Youmna Ghaleb; Mélody Chémaly; Marie-Line Moussalli; Jean-Pierre Rabès; Mathilde Varret; Catherine Boileau
Journal:  Curr Atheroscler Rep       Date:  2014-09       Impact factor: 5.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.